指南与共识妇科肿瘤

上皮性卵巢癌的胚系与体细胞肿瘤检测:ASCO指南

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2020-01-27

该指南针对上皮性卵巢癌患者的遗传与肿瘤检测提出推荐,基于2007至2019年文献的系统综述(纳入19项合格研究)及专家共识。推荐所有患者进行胚系BRCA1/2及其他易感基因检测,胚系阴性者行体细胞BRCA1/2检测,特定组织学类型行错配修复缺陷检测,并强调检测应在诊断时进行。

要点

  • 所有上皮性卵巢癌患者均应进行胚系BRCA1/2及其他易感基因检测。
  • 胚系BRCA1/2阴性者应行体细胞BRCA1/2检测,阳性者接受FDA批准治疗。
  • 透明细胞癌、子宫内膜样癌或黏液性癌应行体细胞错配修复缺陷检测。

核心结论

  • 所有上皮性卵巢癌患者应在诊断时进行胚系遗传检测,胚系BRCA1/2阴性者需补充体细胞BRCA1/2检测。
  • 检出胚系或体细胞BRCA1/2致病/可能致病变异者应接受FDA批准的一线及复发治疗。
  • 透明细胞癌、子宫内膜样癌或黏液性癌应行体细胞错配修复缺陷检测,检出者接受相应FDA批准治疗。

研究设计与样本

  • ASCO指南基于2007至2019年文献系统检索与前瞻性研究选择标准制定。
  • 系统综述纳入19项合格研究,证据包括观察性数据系统综述、共识指南和随机对照试验。

主要发现

  • 系统综述共识别19项符合标准的研究,证据类型涵盖观察性数据系统综述、共识指南及随机对照试验。

关键数值与推荐

  • 所有上皮性卵巢癌患者均应进行胚系BRCA1/2及其他卵巢癌易感基因检测。
  • 胚系BRCA1/2致病/可能致病变异阴性者应行体细胞肿瘤BRCA1/2致病/可能致病变异检测。
  • 检出胚系或体细胞BRCA1/2致病/可能致病变异者应接受FDA批准的一线及复发治疗。
  • 透明细胞癌、子宫内膜样癌或黏液性卵巢癌患者应行体细胞错配修复缺陷检测,检出者接受FDA批准治疗。
  • 不确定意义变异不应作为临床决策依据。

临床怎么用

  • 上皮性卵巢癌患者应在诊断时进行检测,遗传评估应与熟悉遗传性肿瘤诊治的医疗提供者共同完成。
  • 已知胚系致病性癌症易感基因变异患者的血液一级或二级亲属应接受个体化遗传风险评估、咨询和检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide recommendations on genetic and tumor testing for women diagnosed with epithelial ovarian cancer based on available evidence and expert consensus. METHODS: A literature search and prospectively defined study selection criteria sought systematic reviews, meta-analyses, randomized controlled trials (RCTs), and comparative observational studies published from 2007 through 2019. Guideline recommendations were based on the review of the evidence. RESULTS: The systematic review identified 19 eligible studies. The evidence consisted of systematic reviews of observational data, consensus guidelines, and RCTs. RECOMMENDATIONS: All women diagnosed with epithelial ovarian cancer should have germline genetic testing for BRCA1/2 and other ovarian cancer susceptibility genes. In women who do not carry a germline pathogenic or likely pathogenic BRCA1/2 variant, somatic tumor testing for BRCA1/2 pathogenic or likely pathogenic variants should be performed. Women with identified germline or somatic pathogenic or likely pathogenic variants in BRCA1/2 genes should be offered treatments that are US Food and Drug Administration (FDA) approved in the upfront and the recurrent setting. Women diagnosed with clear cell, endometrioid, or mucinous ovarian cancer should be offered somatic tumor testing for mismatch repair deficiency (dMMR). Women with identified dMMR should be offered FDA-approved treatment based on these results. Genetic evaluations should be conducted in conjunction with health care providers familiar with the diagnosis and management of hereditary cancer. First- or second-degree blood relatives of a patient with ovarian cancer with a known germline pathogenic cancer susceptibility gene variant should be offered individualized genetic risk evaluation, counseling, and genetic testing. Clinical decision making should not be made based on a variant of uncertain significance. Women with epithelial ovarian cancer should have testing at the time of diagnosis.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020. PMID: 31986064. doi:10.1200/JCO.19.02960

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。